The Effect of Tranexamic Acid on Blood Loss and Transfusion Requirements Following Open Femur Fracture Surgery

• Status: Withdrawn
• Trial end date: 2021-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effect of tranexamic acid (TXA) on blood loss and transfusion requirements in patients with femur fractures requiring open surgical approaches.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas Health Science Center, Houston
• Treatments: Anesthetics; Tranexamic Acid

Criteria

Inclusion Criteria:

• Patients admitted to Memorial Hermann Medical Center with acute femur fractures that require open surgical approaches for fracture reduction and implant application, including patients with subtrochanteric, high-energy intertrochanteric, periprosthetic, and intra-articular distal femur fractures.

Exclusion Criteria:

• Preoperative use of any anticoagulant

• History of deep venous thrombosis or pulmonary embolus

• Allergy to TXA

• Hepatic dysfunction (AST/ALT > 60)

• Renal dysfunction (Cr > 1.5 or GFR < 30)

• History of cerebrovascular accident in the past 12 months

• Active coronary artery disease (event in the past 12 months)

• Presence of drug-eluting stent

• Color blindness

• Presence of an additional acute injury that could contribute to blood transfusion requirements